BLAINJECTIONINJECTABLE
Approved
Nov 2019
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
4/8 — Partial
ZIEXTENZO (pegfilgrastim-bmez) by Novartis is colony-stimulating factors that act on hematopoietic cells by binding to specific cell surface receptors, thereby stimulating proliferation, differentiation, commitment, and end cell functional activation. Approved for leukocyte growth factor [epc]. First approved in 2019.
Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZIEXTENZO (pegfilgrastim-bmez) is a biosimilar granulocyte colony-stimulating factor (G-CSF) cytokine administered by injection to stimulate white blood cell production. It is indicated for reducing the duration of severe neutropenia and associated complications in patients receiving myelosuppressive chemotherapy. The drug works by binding to G-CSF receptors on bone marrow progenitor cells to promote neutrophil proliferation and differentiation.
$10MPart D
PeakStable
At peak lifecycle with modest Part D spending of $10M, this biosimilar maintains steady market presence but faces intense competitive pressure, suggesting mid-sized commercial team focused on penetration and cost-based differentiation.
Mechanism of Action
colony-stimulating factors that act on hematopoietic cells by binding to specific cell surface receptors, thereby stimulating proliferation, differentiation, commitment, and end cell functional activation.
Pharmacologic Class:
Leukocyte Growth Factor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ZIEXTENZO offers exposure to biosimilar strategy, regulatory compliance, and value-based market access in a competitive oncology support segment. The modest job count (4 linked roles) and R&D/Legal focus indicate a specialized, smaller team with emphasis on biosimilar science, comparative efficacy, and ethics rather than large-scale commercial expansion.
Executive Director
Worked on ZIEXTENZO at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.